Search

Crinecerfont

[L51973] When administered alongside glucocorticoid replacement in patients with CAH it allows for the use of lower, physiological doses for glucocorticoid replacement, thereby reducing the risks associated … [A264818] Crinecerfont was approved by the FDA in December 2024 as an adjunct to glucocorticoid replacement in patients with CAH.[L51973,L51993]

Damoctocog alfa pegol

In recent years, various extended half-life factor VIII and factor IX preparations have been studied and gained approval. … In order to extend half-lives, techniques such as fusion to protein conjugates (Fc part of IgG1 or albumin), chemical modification (PEGylation), and protein sequence modification have been utilized.

Fluoride ion

Its various salt forms and minerals play numerous roles as chemical reagents, industrial chemicals, and commercial products. … Fluoride ions are found in various minerals but are only present in trace amounts in water.

Ferric pyrophosphate

The ferric ion is strongly complexed by pyrophosphate.[A31979] It presents an increasing interest as this insoluble form can be milder in the gastrointestinal tract and present higher bioavailability. … Free iron presents several side effects as it can catalyze free radical formation and lipid peroxidation as well as the presence of interactions of iron in plasma.

VX-702

In the future, VX-702 may be investigated for combination with methotrexate, a commonly used therapy for RA. … VX-702 is a small molecule investigational oral anti-cytokine therapy for treatment of inflammatory diseases, specifically rheumatoid arthritis (RA). It acts as a p38 MAP kinase inhibitor.

Lumiracoxib

On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver … Lumiracoxib is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID).

Pentastarch

It is sold under the name Pentaspan by Bristol-Myers Squibb and is used for fluid resuscitation. … When administered, pentastarch remains mainly in the circulatory system and hence, it is considered a plasma expander.

Lemborexant

[L10863] Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to … Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

Calcium phosphate dihydrate

Alclofenac

Alclofenac is a non-steroidal anti-inflammatory drug. It was withdrawn from the market in the United Kingdom in 1979.